Current Studies

PI: Ziva Cooper, PhD

This clinical trial will examine the effects of combining THC and cannabigerol on pain and other outcomes.

PI: Giordano de Guglielmo, PharmD, PhD

The development of novel and more effective medications for alcohol use disorder (AUD) is a pressing medical need. Preclinical studies showed that chronic cannabidiol (CBD) treatment decreased alcohol drinking and prevented the reinstatement of alcohol seeking that was induced by environmental cues and stress.

PI: Scott Letendre, MD

This is a clinical study looking at the intersection of cannabis, HIV, and the Central Nervous System.

PI: William Perry, Ph.D. & Jared Young, Ph.D

This study will look at the impact of chronic cannabis use as well as the effects of acute administration of the principal constituents of cannabis on cognition and brain levels of endogenous cannabinoids and the neurotransmitter dopamine.

PI: Jennifer Iudicello, PhD

This study will examine the effects of chronic cannabis use and the role of the endocannabinoid system on persistent inflammation in people with HIV.

PI: Brook Henry, Ph.D. & Ron Ellis, M.D., Ph.D.

This study will address these three fundamental gaps in our knowledge by: 1) examining the acute effects of various CBD/THC products on HIV-NP, 2) utilizing a mHealth text messaging protocol (Individual Monitoring of Pain and Cannabis Taken or IMPACT) to monitor daily real-world cannabis use and changes in pain; 3) studying the relationship between cannabinoids, EC biomarkers, and chronic neuropathic pain.

PI: Kristin Cadenhead, MD

This clinical trial will explore the effectiveness of cannabidiol (CBD), in reducing symptoms and improving cognition in early psychosis. Additionally, this trial will examine the effect of CBD on the biological response to stress, and the effect of CBD on eating behavior induced by antipsychotic medication.

PI: Ron Ellis, MD, PhD

This study will examine the microbiome and endocannabinoid system in people with HIV and how they relate to neuroinflamation and the blood-brain-barrier.

PI: Nathaniel Schuster, MD

This is a clinical study to determine the effect of THC and CBD on acute migraine.

PI: Charles Taylor, PhD

This is a clinical study to determine the effect of CBD on anxiety disorders.

PI: Nicholas DiPatrizio, PhD

This study will examine the impact of cannabis exposure on gut barrier function in metabolic disease and experimental colitis

PI: Doris Trauner, MD

This clinical trial is examining if and how cannabidiol (CBD), a chemical found in the cannabis plant, provides therapeutic benefit to children with severe autism spectrum disorder (ASD). The trial is funded by a grant from the Ray and Tye Noorda Foundation in partnership with and based on recommendations from the Wholistic Research and Education Foundation.

PI: Jeremy Pettus, MD

This study will seek to determine the effects of THC use on glucose metabolism

PI: Guido Frank, MD

Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa (AN), a disorder with high chronicity and mortality, many individuals seek out alternative approaches to care.  Recent evidence has suggested that exaggerated anxiety and diminished reward or motivation to eat play a key role in causing AN symptoms and poor outcome. 

PI: Erin Morgan, PhD

This study will examine whether CBD will reduce alexithymia and inflammation in people with HIV

PI: Michael Taffe, PhD

This study will examine the effects of cannabis and cannabinoids on the behavioral and molecular outcomes of motivational and stress-mediated changes associated with prescription oxycodone addiction and dependence.

PI: Veena Ranganath, MD

The overall goal of this proof-of-principle proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of Rheumatoid Arthritis (RA) patients with moderate to severe disease activity.

PI: Arpi Minassian, PhD

This study will utilize a cross-species approach to delineate the effects EC system activation has on HIV-relevant cognitive and motivational domains.